Immune SupportLimited ResearchResearch OnlyB

KPV

α-MSH C-terminal tripeptide · MC1R and MC3R partial agonism; NF-κB nuclear translocation inhibition; direct intracellular uptake reducing pro-inflammatory cytokines (IL-1β, TNF-α, IL-8, IL-6); inhibition of caspase-1 and NLRP3 inflammasome activation

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts use live PeptIQ self-reports.

Studies cited
7
Research grade
B
Experience
99

Overall check-ins

Activity
49

Trackers & reports

Typical Dose

500 mcg–2 mg daily (research protocols)

Route

Injectable

Cycle

Protocol-dependent

Storage

2–8°C Refrigerated

What is KPV?

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.

Mechanism of Action

MC1R and MC3R partial agonism; NF-κB nuclear translocation inhibition; direct intracellular uptake reducing pro-inflammatory cytokines (IL-1β, TNF-α, IL-8, IL-6); inhibition of caspase-1 and NLRP3 inflammasome activation

Target: MC1R, MC3R, NF-κB, NLRP3 inflammasome

Research Indications

Immune ModulationEffective

Research shows modulation of immune cell activity and inflammatory response

Inflammation ControlEffective

May reduce systemic and localized inflammatory markers

Infection ResistanceModerate

Some evidence for improved pathogen defense mechanisms

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose250 mcg3x weeklySubcutaneous injection
Maintenance Dose500 mcgWeeklySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Consult prescriber before combining with any medicationCaution
BPC-157Compatible
NAD+Compatible
Vitamin DCompatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove KPV vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial effects and adaptation period. Monitor for any adverse reactions.

Week 2–4

Primary effects begin to manifest. Adjust dosing as recommended by your provider.

Week 4–8

Main therapeutic effects should be established. Assess progress with your provider.

Week 8+

Evaluate results and determine continuation, cycling, or dose adjustments.

Side Effects & Safety

  • Injection site reactions (redness, bruising, mild pain)
  • Potential for allergic reaction — discontinue if rash or hives occur
  • Individual reactions vary — start at the lowest dose and monitor carefully
  • Consult your healthcare provider before use and report any unusual symptoms

FDA Status & Regulatory Info

Research Only

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.

Rx Required: No
503A Ban: No
Telehealth: Available
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 54 users report

Observational self-reports from live PeptIQ aggregates. Not clinical outcomes.

54 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 98% · Mixed 2% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
210
Mood
210

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.2–3 mg

0.2–0.4 mg
116
0.4–0.6 mg
89
0.6–1 mg
3
1–2 mg
1
2–3 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 60 days · Based on 43 repeat reporters

Share Your Experience

Rate KPV in the PeptIQ app and help the community make informed decisions.

Research References (6)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    KPV tripeptide exerts anti-inflammatory effects in intestinal epithelial cells

    Brzoska T, Luger TA, Maaser C, et al. Dig Dis Sci. 2010

    Source
    Wiki study page →
  2. PubMed

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

    Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008

    Source
    Wiki study page →
  3. PubMed

    alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells

    Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    KPV peptide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    The neuroimmunomodulatory peptide alpha-MSH

    Ichiyama T, Sato S, Okada K, et al. Annals of the New York Academy of Sciences. 2000

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for KPV.

Often tracked with

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your KPV protocol in PeptIQ

Turn this KPV guide into a living protocol — doses, vials, and history in one place.

Track KPVOpen web app

iOS, Android, and web

Partner clinic

Licensed clinics can help you explore KPV treatment options online — if it's a fit for you.

Partner link. PeptIQ may earn a referral fee. Not medical advice.

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
~1 hour (estimated)
Target
MC1R, MC3R, NF-κB, NLRP3 inflammasome
Route
Injectable
Availability
Research only
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss KPV with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for KPV.

Often tracked with